Chronic hepatitis B virus (HBV) infection is common among HIV-infected patients because of shared epidemiological risks [1, 2] . The regional differences of seroprevalence of such coinfection exist, however, depending on the major routes for HIV transmission and epidemiology of HBV infection in the general population. For example, the prevalence of chronic HBV infection in HIV-infected patients ranges 6%-10% in
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Impact of Chronic Hepatitis B Virus (HBV) Infection on Outcomes of Patients Infected with HIV in an Area Where HBV Infection Is Hyperendemic
Chronic hepatitis B virus (HBV) infection is common among HIV-infected patients because of shared epidemiological risks [1, 2] . The regional differences of seroprevalence of such coinfection exist, however, depending on the major routes for HIV transmission and epidemiology of HBV infection in the general population. For example, the prevalence of chronic HBV infection in HIV-infected patients ranges 6%-10% in Western countries, where sharing needles and homosexuality are the 2 major routes of HIV transmission [1] [2] [3] [4] [5] . In countries where vertical transmission of HBV is prevalent, the seroprevalence of HBV coinfection among HIV-infected patients may be different, although such data are rarely reported [6, 7] .
HBV infection has been regarded as an opportunistic infection of HIV-infected patients [8] , and coinfection with HIV and HBV may cause complex interactions [9] , because HIV impairs the cellular immunity leading to increased replication of HBV [4, [10] [11] [12] and HBV enhances HIV replication by activation of inflammatory cytokines and transcriptional factor (nuclear factor kB) [13] . However, clinical studies performed before introduction of HAART evaluating the impact of HBV coinfection on the clinical outcomes of HIV-infected patients yielded inconsistent results [3, 10, [14] [15] [16] . Such inconsistencies may result from different study designs and study populations. In addition, the impact of HBV on outcomes of HIV-infected patients may be overshadowed by the opportunistic illness (OI) before introduction of HAART, which may result in early mortality before development of chronic hepatic complications. With HAART, the prognosis of HIV-infected patients has been dramatically improved [17] . Longer survival may allow us to discern the emergence of comorbidities related to chronic HBV infection. However, such clinical studies of the interactions between HBV and HIV infection remain limited in the era of HAART [8, 16] .
In this 8-year prospective observational study, we aimed to investigate the impact of HBV infection on the immunologic, virologic, and clinical responses and the mortality of 498 nonhemophiliac HIV-infected patients who were treated with antiretroviral therapy (ART), especially HAART, in Taiwan, where HBV infection is hyperendemic and where the seroprevalence of HBV (hepatitis B surface antigen [HBsAg] positive) was estimated to be 15%-20% before nationwide HBV vaccination was initiated in 1984 [18, 19] .
PATIENTS AND METHODS
Patients and setting.
Consecutive nonhemophiliac HIVinfected patients observed at the National Taiwan University Hospital (Taipei) who were HBsAg positive at study entry and 6 months later (chronic HBV infection) between June 1994 and June 2002 were enrolled in this prospective observational study, which ended on 28 February 2003. To avoid confounding effects of hepatitis C virus (HCV) coinfection, patients with positive anti-HCV antibody were excluded from analysis. During the study period, the treatment of chronic HBV infection was limited to lamivudine; newer therapeutic agents, such as adefovir or tenofovir, were not commercially available in Taiwan. A standardized case collection form was used to prospectively record data of demographic characteristics; risk factors for HIV transmission; results of laboratory, pathologic, and radiologic investigations; ART; and outcomes.
Laboratory tests and radiographic investigations. Liver function tests, including serum aminotransferase values and bilirubin level, and CD4 cell count and plasma HIV RNA virus load (PVL), were determined every 3-4 months. PVLs were quantified with RT-PCR (version 1.5; Roche Amplicor), with a lower detection limit of 400 (2.60 log 10 ) copies/mL, and CD4 cell counts were determined with FACFlow (Becton Dickinson).
HBsAg and anti-HBs antibody were determined by EIA (Abbott Laboratories), and anti-HCV antibody by commercialized microparticulate EIA (Axsym HCV, version 3.0; Abbott). RT-PCR within the NS 5 NC gene (Cobas Amplicor HCV monitor, version 2.0; Roche Diagnostics) was performed in available blood specimens from 1 of every 2 consecutively enrolled patients of both groups who had a baseline CD4 count of р cells/L. Abdominal sonography and quantification of a-fetoprotein level were performed in patients with HBV infection once per year. In patients with abnormal liver function test findings or abdominal symptoms, abdominal sonography was performed on an as-needed basis. CT of the abdomen was performed when a space-occupying lesion was detected by abdominal sonography.
Liver pathology and quantification of HBV DNA at the time of clinical hepatitis. During the study period, 82 patients underwent liver biopsy; 29 patients had the biopsy performed when hepatitis was diagnosed. The biopsy specimens were submitted for immunohistochemical staining of HBsAg and HBcAg in addition to routine staining and microbiological cultures. HBV DNA was extracted from 200 mL of serum samples of 29 of 39 HBV-coinfected patients at the time of hepatitis with the High Pure Viral Nucleic Acid Kit (Roche Molecular Biochemicals), and real-time PCR was performed with a LighterCycler instrument (Roche Molecular Biochemicals) according to the manufacturer's instructions. It was estimated that the sensitivity was 0.001 pg/mL of HBV DNA, which approximately corresponded to 10 2 copies/mL. Assessment of virologic and immunologic responses to ART and HIV progression. Virologic failure was defined as failure to achieve an undetectable PVL after receipt of HAART for у4 months. Patients with missing PVL data for an interval of у6 months also counted as failure (intention-to-treat principle). Immunologic response was assessed by the change of CD4 cell count from baseline to within 6 months of the end of study or patient death and by the proportion of patients achieving an increase of CD4 cell count by у cells/L during the 6 100 ϫ 10 follow-up period. HIV progression was assessed as relapses or development of AIDS-defining OIs [20] 1 month after study entry. To better define the mortality rate and survival duration, we searched the data of mortality reports from Vital Statistics of the Department of Health, Taiwan (Taipei), to identify deaths in patients who might be observed at other designated hospitals for HIV care.
Definitions. Hepatitis was defined as an increase in the serum aspartate aminotransferase and alanine aminotransferase levels у5-fold of normal (reference aspartate aminotransferase level: men, р37 U/L, women, р31 U/L; reference alanine aminotransferase level, men, р41 U/L, women, р31 U/L); and hyperbilirubinemia as a total serum bilirubin level of у2 mg/ dL with 150% of conjugated bilirubin without evidence of hemolysis. Hepatic decompensation was defined according to the Child-Pugh criteria classified B or C [21] as presence of hepatic encephalopathy, coagulopathy, ascites, and prolonged hyperbilirubinemia for у3 months, which was not attributable to concurrent opportunistic infections or malignancies and other medical causes. HAART was defined as the combination of у3 antiretroviral agents containing protease inhibitors or Baseline total bilirubin level, median mg/dL (range) 0.5 (0.1-1.9) 0.5 (0-1.6) .87
NOTE. Serum anti-HCV-positive patients were excluded. ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; OI, opportunistic illness; PI, protease inhibitor; PVL, plasma virus load. a CD4 lymphocyte count and PVL data were available for 107 and 52 of HBV-infected patients, respectively, and for 370 and 224 of non-HBV-infected patients, respectively. b AIDS-defining opportunistic illness was defined according to the 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults [20] ; baseline OI was defined as an OI that developed within 1 month of enrollment.
nonnucleoside reverse-transcriptase inhibitors. Cirrhosis of the liver was diagnosed if cirrhotic changes of liver pathology or the presence of coarse and heterogeneous echotexture and irregular shrinkage of liver surface accompanied with ascites, collateral vasculature, or splenomegaly were detected by sonography or CT. Statistical analysis. All statistical analyses were performed by SAS statistical software, version 8.2 (SAS Institute). Categorical variables were compared by x 2 or Fisher's exact test; noncategorical variables were compared by the Wilcoxon rank sum test. Logistic regression was used to assess the impact of HBV coinfection on the risk for acute hepatitis, progression of HIV disease with adjustment for age, sex, and risk behavior for HIV transmission, year enrolled, baseline CD4 cell count and PVL, baseline OI, and use of HAART. ORs and 95% CIs were calculated for logistic regression analyses. The survival probabilities were estimated by Kaplan-Meier method. The Cox proportional-hazard model was used to compare the difference of mortality between the 2 groups with adjustment for age, sex, risk behavior for HIV transmission, year enrolled, baseline CD4 count and PVL, baseline OI, and use of HAART. Hazard ratios and 95% CIs were calculated for survival analyses.
Patients with hepatitis and hyperbilirubinemia at presentation were excluded for analysis of acute hepatitis and hyperbilirubinemia, unless a new episode was documented. The mortality rate for each group was calculated as number of deaths per 100 person-years of observation. Exact 95% CIs for mortality rates were calculated on the basis of the Poisson distribution. The duration of survival for patients was estimated from date of enrollment to death, loss to follow-up at this hospital and other designated hospitals in Taiwan, or by 28 February 2003.
RESULTS
Patients.
Over the 8-year study period, 126 (21.7%) of 581 HIV-infected patients received a diagnosis of chronic HBV infection. Eighty-three patients who had positive anti-HCV antibody were excluded (15 HBV-infected and 68 of HBVuninfected patients). Therefore, 498 patients, 457 men and 41 women, were included for further analysis. The baseline demographic and clinical characteristics are summarized in table 1. There were no significant differences regarding baseline characteristics between HBV-infected and HBV-uninfected patients, with an exception that baseline aminotransferase levels were higher in HBV-infected patients than in HBV-uninfected patients.
Immunologic and virologic responses to HAART and HIV progression. The effects of HBV serostatus on clinical, immunologic, and virologic responses to HAART of HIV-infected patients are shown in table 2. The median increase of CD4 cell count from baseline was comparable between the 2 groups; , by log-P ! .0001 rank test. , by the log-rank test. P p .41 53.3% of HBV-infected patients and 57.9% of HBV-uninfected patients had an increase of CD4 count by у cells/L 6 100 ϫ 10 ( ). HBV-infected patients had a higher rate of virologic P p .37 failure than did those without (adjusted OR [AOR], 1.76; 95% CI, 1.03-2.99). HBV serostatus had no effect on HIV progression, however. Similar proportions of the HBV-infected patients (23.4%) and HBV-uninfected patients (21.2%) developed new AIDS-defining OIs (AOR, 0.94; 95% CI, 0.53-1.66).
Hepatitis and hepatic decompensation. Over the median observation duration of 756 days (range, 2-3172 days), more HBV-infected patients developed hepatitis, hyperbilirubinemia, and hepatic decompensation (table 2 and figure 1 ). In total, 102 (20.5%) of 498 HIV-infected patients developed hepatitis (35.1% of HBV-infected patients vs. 16.3% of HBV-uninfected patients; adjusted hazard ratio [AHR], 2.54; 95% CI, 1.69-3.82). The interval between initiation of lamivudine and development of hepatitis was 32 days (range, 1-1120 days). Of the 111 HBV-infected patients, 56 (68%) of 82 patients were positive for HBeAg. There was no significant difference for hepatitis between patients with and without positive HBeAg (AOR, 1.08; 95% CI, 0.41-2.83;
). Of the 19 HBV-P p .88 infected patients undergoing liver biopsy at the time of hepatitis, the pathological diagnosis of hepatitis were drug-related hepatitis ( ), mycobacterial infection ( ), toxoplasn p 5 n p 5 mosis ( ), hepatocellular carcinoma ( ), and lymn p 1 n p 1 phoma ( ). Nine (47%) of the 19 biopsy specimens were n p 1 positive for HBsAg or HBcAg of hepatocytes by immunohistochemical staining, suggesting acute exacerbation of chronic hepatitis. Of the 10 HBV-uninfected patients, the pathological diagnoses of hepatitis were drug-related hepatitis ( ), Kan p 8 posi's sarcoma ( ), and mycobacterial infection ( ). n p 1 n p 1 Eleven (9.91%) of 111 HBV-infected patients developed hepatic decompensation, compared with 2 (0.52%) of 387 non-HBV-infected patients (AOR, 9.94; 95% CI, 1.89-52.35). Liver biopsy of the 2 HBV-uninfected patients with hepatic decompensation revealed drug-related cholestasis due to trimethoprim-sulfamethoxazole and itraconazole in one and mycobacterial infection in the other. The HBV-infected patients who initiated ART containing lamivudine appeared to have a lower risk for hepatitis: 14 (20.3%) of 69 receiving lamivudine versus 25 (59.5%) of 42 not receiving lamivudine, although this difference did not reach statistical significance (AOR, 0.38; 95% CI, 0.14-1.03;
). P p .06 Mortality. One hundred forty-one patients died during the follow-up period (table 2). The AHR for death in HBVinfected patients compared with HBV-uninfected patients was 1.71 (95% CI, 1.19-2.47). The risk for death increased significantly in HBV-infected patients in the era of HAART. Before introduction of HAART, the AHR for death of HBV-infected patients compared with HBV-uninfected patients was 1.15 (95% CI, 0.55-2.41), and after HAART, the AHR was 2.28 (95% CI, 1.42-3.67) (figures 2 and 3). All but 8 deaths of the patients were due to complications of AIDS-defining OIs or events unrelated to HIV infection (table 2). All of the 8 fatalities related to hepatic complications occurred in HBV-infected patients; the complications included fulminant viral hepatitis ( ), n p 2 liver cirrhosis with hepatic decompensation ( ), hepatitis n p 2 due to HBV infection and antimicrobial or antiretroviral drugs ( ), and hepatocellular carcinoma ( ). n p 3 n p 1
DISCUSSION
In our HIV-infected patients, few of whom acquired HIV infection through injection drug use, the rate of chronic HBV infection (21.7%) appears to be higher than those of Western countries, where injection drug use and male-male sex are the most 2 most common routes of HIV transmission [1] [2] [3] [4] [5] . The , by the log-rank test. P p .0009 higher rate of chronic HBV infection in our HIV-infected patients may have been related to the higher background rate (15%-20%) of vertical transmission for HBV [18, 19] .
HBV and HIV coinfection leads to complex virologic interactions. HBV has been shown to activate HIV replication directly [13] , and chronic and persistent activation of the immune system by HBV infections may accelerate immunodeficiency and the course of the HIV infection [8, 14] . Whether such in vitro phenomena may reflect on the immune recovery in patients receiving effective ART is still unknown. In this study of a median observation for 2 years, both patient groups had a similar immunologic response, as assessed by increase of CD4 lymphocyte count, and HBV infection did not increase risk for developing new AIDS-defining OIs, compared with lack of HBV infection. Therefore, the immunologic response to HAART was not affected by HBV infection, despite the fact that most of our patients were at advanced stages of HIV infection. However, our patients with chronic HBV infection had a higher rate of virologic failure after HAART, which might have been related to the higher incidence of hepatitis resulting in higher rate of treatment interruption. Whether the less favorable virologic response to HAART of HIV-infected patients with chronic HBV infection may eventually lead to development of AIDS-related diseases in a longer duration of follow-up needs further study.
Chronic viral hepatitis has been shown to be associated with the development of severe hepatotoxicity during protease inhibitor-or nonnucleoside reverse-transcriptase inhibitorcontaining ART. The mechanism may be either a direct toxic effect of ART or enhanced inflammatory response against HBVinfected hepatocytes [5, [22] [23] [24] [25] . In comparison with previous studies of patients at an earlier stage of HIV infection [4, 5, 22, 23, 26, 27] , we found an even higher rate of hepatitis, with one-third of the patients with HBV coinfection developing hepatitis and nearly 10% developing hepatic decompensation after initiation of ART. Many studies have suggested that immune reconstitution after HAART is causative in hepatitis in addition to hepatotoxicity of ART [5, 22, [24] [25] [26] [27] . Cell-mediated immunity may play a central role in the pathogenesis of HBV; thus, patients with advanced HIV infection may have less liver inflammation [28] . This higher rate of hepatitis may be because most of our patients were at the advanced stage of HIV infection, experiencing OIs, and receiving multiple therapeutic or prophylactic antimicrobials in addition to ART [29] .
The exact causes of hepatitis may be multifactorial and are difficult to determine in this patient population because not all patients with hepatitis underwent liver biopsies and PCR testing. With a limited number of HBV-infected patients undergoing liver biopsy and quantifications of HBV DNA level at the time of hepatitis, we found that ∼50% of the cases of hepatitis could be attributed to exacerbation of HBV infection. With better virologic and immunologic responses, patients enrolled in the era of HAART had a lower risk for hepatitis when systemic OIs have been controlled, and concurrent hepatotoxic antimicrobials for treatment or prophylaxis can be discontinued safely.
Efficacy of lamivudine against HBV has been demonstrated in HIV-infected patients in combination with ART [30, 31] . Of patients coinfected with HBV and HIV, discontinuation of lamivudine may result in relapses of hepatitis [22, 32] . In this study, we demonstrated a trend, although it was not statistically significant, toward reduction of risk for acute hepatitis in patients receiving ART containing lamivudine. The statistical insignificance may be related to the fact that our case number was small. Whether lamivudine may also reduce risks for chronic hepatic complications and increase potential risk for selection of drug-resistant HBV and HIV needs further study [33, 34] .
In the HAART era, mortality and morbidity has decreased dramatically among HIV-infected patients with access to antiretroviral care, and longer durations of survival may allow morbidity and mortality related to chronic HBV infection to emerge. In this study, we found that patients with chronic HBV and HIV coinfection had a lower overall survival rate. No survival difference of the 2 patients groups was observed before the era of HAART because most patients died of OIs. Although AIDS-defining OIs remain the leading cause of death in the era of HAART, the statistically significant survival difference between the 2 groups resulted from more deaths related to hepatic complications. Our study results echo the findings of Louie et al. [35] , who found that deaths attributable to chronic hepatic complications are assuming an increasingly important role in the era of HAART.
In conclusion, in HIV-infected patients, HBV coinfection did not have an adverse impact on the recovery of CD4 lymphocyte count and on the development of new OIs after initiation of HAART. Therefore, chronic HBV infection should not be a deterrent to initiation of ART. However, HBV coinfection is associated with an increased risk of virologic failure, acute hepatitis, hepatic decompensation, and mortality. HBV vaccination in HIV-infected patients should be encouraged, and careful monitoring of liver function tests should be performed in HIVinfected patients with HBV coinfection who receive ART.
